☀️ Solriamfetol Dopamine-Norepinephrine Reuptake Simulator

Baseline Dopamine-Norepinephrine Synaptic Transmission

Healthy wakefulness relies on tightly regulated dopamine and norepinephrine reuptake.

• ~1 in 2,000: Narcolepsy prevalence (US adults)
• Milliseconds: DAT reuptake speed (per cycle)
• VTA & LC: Wake-promoting nuclei (dopamine, norepinephrine)
• Short: Baseline cleft dwell time (rapid clearance)

Dopamine transporter function

DAT rapidly pulls dopamine back into the presynaptic terminal.

Norepinephrine transporter function

NET clears norepinephrine to terminate each signaling pulse.

Narcolepsy and low arousal tone

Narcolepsy reflects weakened wake-promoting neurotransmitter signaling.

Standard reuptake keeps synaptic dopamine and norepinephrine transient, not sustained.

Solriamfetol Enters the Synaptic Cleft

Oral solriamfetol is absorbed and distributes to central dopaminergic and noradrenergic synapses.

• 37.5–150 mg: Approved dose range (once daily)
• ~2 h: Time to peak plasma (Tmax)
• DAT + NET: Selectivity (dual inhibitor)
• Minimal: Serotonin activity (unlike some stimulants)

Oral absorption and distribution

Solriamfetol crosses into brain tissue and reaches synaptic terminals.

Transporter-seeking behavior

Drug molecules diffuse toward DAT and NET binding sites.

Dose-dependent occupancy

Higher doses occupy more transporters at the presynaptic membrane.

Solriamfetol binds transporters directly, unlike drugs that trigger extra release.

Transporter Blockade Halts Reuptake

Bound solriamfetol molecules occupy DAT and NET, physically blocking neurotransmitter reuptake.

• DNRI: Mechanism class (dual reuptake inhibitor)
• High: Blockade at 150 mg (near-saturating)
• Extended: Cleft dwell time (vs baseline)
• ~1–2 h: Onset of blockade (post-dose)

Competitive transporter occupancy

Drug molecules lock onto transporters, preventing neurotransmitter re-entry.

Neurotransmitter accumulation

Unrecaptured dopamine and norepinephrine build up in the cleft.

Dose-response relationship

Blockade percentage scales with circulating drug concentration.

Blocked transporters cannot clear neurotransmitter, so cleft levels rise.

Prolonged Dopamine and Norepinephrine Activity

Lingering neurotransmitter drives stronger, longer postsynaptic receptor activation.

• Increased: Receptor occupancy (D2/D3, alpha-1)
• Prolonged: Signal duration (vs single pulse)
• Amplified: Wake drive (cortical arousal)
• ~3–5 h: Peak effect window (post-dose)

Postsynaptic receptor binding

More neurotransmitter means more frequent receptor activation.

Arousal circuit amplification

Enhanced dopamine and norepinephrine tone activates cortical arousal.

Sustained wake-promoting drive

Signaling stays elevated through several hours after dosing.

Enhanced signaling, not extra release, is solriamfetol's core mechanism.

Reduced Excessive Daytime Sleepiness

Sustained dopamine-norepinephrine enhancement translates into measurable daytime alertness gains.

• Significant: MWT improvement (maintenance of wakefulness test)
• Clinically meaningful: ESS score reduction (Epworth Sleepiness Scale)
• Once-daily: Duration of benefit (dosing coverage)
• Narcolepsy, OSA: Indicated conditions (excessive sleepiness)

Alertness across the day

Wakefulness gains persist for hours after morning dosing.

Comparison to stimulant classes

Solriamfetol acts without strong dopamine-releasing stimulant effects.

Therapeutic window management

Dose titration balances alertness benefit against side effects.

Clinical trials link higher doses to greater daytime wakefulness gains.